Browsing Tag
Phase 2 Trials
2 posts
Will ZEPHYR and IRIS data position MapLight Therapeutics, Inc. as a scalable CNS innovator?
MapLight Therapeutics nears dual CNS data readouts. Discover how ZEPHYR and IRIS could shape its strategy and market positioning.
Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has…